Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2026-03-11 Regulatory Filings
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
As per attachment
Regulatory Filings
2026-03-11 English
General Updates
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a Postal Ballot issued by GlaxoSmithKline Pharmaceuticals Limited. It includes information about the appointment and remuneration of a Whole-time Director & Chief Financial Officer, voting instructions, regulatory references to SEBI Listing Obligations and Disclosure Requirements Regulations, and the Companies Act. The document is not a report itself but a notice seeking shareholder approval via postal ballot and electronic voting. It contains no financial statements or management discussion but is a formal communication to shareholders about voting on corporate governance matters. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2026-03-07 English
As per attachment
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice of a Postal Ballot issued by GlaxoSmithKline Pharmaceuticals Limited. It includes information about the appointment and remuneration of a Whole-time Director & Chief Financial Officer, voting instructions, regulatory references to SEBI Listing Obligations and Disclosure Requirements Regulations, and the Companies Act. The document is not a report of financial results or management discussion but a formal notice seeking shareholder approval via postal ballot. It is not announcing voting results but the notice itself. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2026-03-07 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice of a Postal Ballot issued by GlaxoSmithKline Pharmaceuticals Limited. It includes information about the appointment and remuneration of a Whole-time Director & Chief Financial Officer, voting instructions, regulatory references to SEBI Listing Obligations and Disclosure Requirements Regulations, and the Companies Act. The document is not a report itself but a notice seeking shareholder approval via postal ballot and electronic voting. It does not contain financial statements or results but is a communication to shareholders about voting on corporate governance matters. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2026-03-07 English
As per attachment
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a Postal Ballot issued by GlaxoSmithKline Pharmaceuticals Limited. It includes information about the appointment and remuneration of a Whole-time Director & Chief Financial Officer, voting instructions, regulatory references to SEBI Listing Regulations, and compliance with the Companies Act, 2013. The document is not a report itself but a notice seeking shareholder approval via postal ballot. It contains no financial statements or management discussion but is a formal communication to shareholders about voting on corporate governance matters. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2026-03-07 English
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding a regulatory order received from Maharashtra GST authorities. It details a tax demand and penalty related to GST for the period April 2022 to March 2023. The document is short (2329 characters), contains no financial statements or detailed financial analysis, and is primarily an announcement of a regulatory matter. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a legal/tax proceeding but not a full legal proceedings report. Given the nature of the disclosure under SEBI regulations and the absence of detailed legal case information, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance disclosures.
2026-03-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.